#United States #Pittsburgh #PANTHERx Rare #VYKAT XR #Prader-Willi Syndrome

PANTHERx® Rare and Soleno Therapeutics Collaboration: A Milestone in Rare Disease Treatment

PITTSBURGH, March 28, 2025 — PANTHERx® Rare, a prominent leader in the domain of rare disease product accessibility and patient support services in the United States, has made a significant announcement: the company has been chosen by Soleno Therapeutics as the specialized pharmacy responsible for distributing VYKAT™ XR (diazoxide choline extended-release tablets). This groundbreaking treatment is designed for individuals aged four and older afflicted with hyperphagia associated with Prader-Willi syndrome (PWS).

VYKAT™ XR holds the distinction of being the first and only treatment approved by the FDA aimed at managing hyperphagia in those with PWS. Hyperphagia is a chronic condition characterized by intense, relentless hunger that can lead to dangerous behaviors such as food preoccupation and excessive consumption of food and non-food items. This disorder can severely impact the quality of life for patients and their families, with potential life-threatening consequences, including choking and stomach ruptures.

Bansi Nagji, CEO of PANTHERx® Rare Pharmacy, expressed enthusiasm about the partnership: "We are honored to be selected by Soleno Therapeutics for the distribution of VYKAT XR, which represents a major advancement for those dealing with PWS. We are committed to making this vital therapy accessible to the individuals and families who need it."

As a specialty pharmacy, PANTHERx Rare focuses entirely on rare and orphan diseases, ensuring that breakthroughs in medicine reach those they are intended to benefit. The pharmacy is recognized for its comprehensive approach, which combines access solutions with clinical excellence.

Notably, PANTHERx Rare has received dual accreditation, exemplified by its prestigious distinctions in rare disease management, including the Accreditation Commission for Health Care (ACHC) Distinction in Orphan Drugs and the Utilization Review Accreditation Commission (URAC) Rare Disease Center of Excellence. Moreover, PANTHERx has been awarded the MMIT Patient Choice Award seven times and continues to prioritize patient satisfaction in its operations.

Headquartered in Pittsburgh, Pennsylvania, PANTHERx is authorized in all 50 states and U.S. territories, reflecting their extensive reach and commitment to providing support to individuals living with rare and debilitating conditions.

In summary, the collaboration between PANTHERx® Rare and Soleno Therapeutics signifies a momentous leap forward in treating Prader-Willi syndrome and addressing the critical needs of those suffering from hyperphagia. Together, they aim to create meaningful changes in the lives of patients and their families, ensuring that they can access the support and treatments required for a better quality of life.